Radiomics Signature: A Potential Biomarker for the Prediction of Disease-Free Survival in Early-Stage (I or II) Non—Small Cell Lung Cancer

Abstract

Purpose To develop a radiomics signature to estimate disease-free survival (DFS) in patients with early-stage (stage I-II) non-small cell lung cancer (NSCLC) and assess its incremental value to the traditional staging system and clinical-pathologic risk factors for individual DFS estimation. Materials and Methods Ethical approval by the institutional review board was obtained for this retrospective analysis, and the need to obtain informed consent was waived. This study consisted of 282 consecutive patients with stage IA-IIB NSCLC. A radiomics signature was generated by using the least absolute shrinkage and selection operator, or LASSO, Cox regression model. Association between the radiomics signature and DFS was explored. Further validation of the radiomics signature as an independent biomarker was performed by using multivariate Cox regression. A radiomics nomogram with the radiomics signature incorporated was constructed to demonstrate the incremental value of the radiomics signature to the traditional staging system and other clinical-pathologic risk factors for individualized DFS estimation, which was then assessed with respect to calibration, discrimination, reclassification, and clinical usefulness. Results The radiomics signature was significantly associated with DFS, independent of clinical-pathologic risk factors. Incorporating the radiomics signature into the radiomics-based nomogram resulted in better performance (P < .0001) for the estimation of DFS (C-index: 0.72; 95% confidence interval [CI]: 0.71, 0.73) than with the clinical-pathologic nomogram (C-index: 0.691; 95% CI: 0.68, 0.70), as well as a better calibration and improved accuracy of the classification of survival outcomes (net reclassification improvement: 0.182; 95% CI: 0.02, 0.31; P = .02). Decision curve analysis demonstrated that in terms of clinical usefulness, the radiomics nomogram outperformed the traditional staging system and the clinical-pathologic nomogram. Conclusion The radiomics signature is an independent biomarker for the estimation of DFS in patients with early-stage NSCLC. Combination of the radiomics signature, traditional staging system, and other clinical-pathologic risk factors performed better for individualized DFS estimation in patients with early-stage NSCLC, which might enable a step forward precise medicine. RSNA, 2016 Online supplemental material is available for this article.

Radiomics Nomogram Building From Multiparametric MRI to Predict Grade in Patients With Glioma: A Cohort Study

“…These points will be addressed in future work. Second, although we demonstrated that the selected radiomic signatures were associated with tumor grading, it is still difficult to interpret the complex correlation between biochemical processes and tumor features . On the one hand, the underlying pathophysiological processes involved multiple interacting components; on the other hand, the maximized information acquired from computer‐based medical image analysis far exceeds the information that can be obtained by visual observation, which is difficult to exhaustively explain in a biological context.…”

Predictive modeling of outcomes following definitive chemoradiotherapy for oropharyngeal cancer based on FDG-PET image characteristics

“…These features include common statistical features such as the SUV max and quantizations of the intensity-volume histogram distribution of SUV values over the defined ROI volume. Additionally, more complex shape and textural features that take morphological features and second-order gray-level co-occurrence matrix (GLCM)-based features of the analyzed ROI into account were included (Lian et al 2016, Huang et al 2016, Sutton et al 2016, Leijenaar et al 2013). These are further described in the following sections.…”

Radiomics Features of Multiparametric MRI as Novel Prognostic Factors in Advanced Nasopharyngeal Carcinoma

“…By converting medical images into highdimensional, mineable, and quantitative imaging features via high-throughput extraction of data-characterization algorithms, radiomics methods provide an unprecedented opportunity to improve decision-support in oncology at low cost and noninvasively (14,17). Some previous studies have shown that biomarkers based on quantitative radiomics features are associated with clinical prognosis and underlying genomic patterns across a range of cancer types (18)(19)(20)(21)(22).…”